Antidiabetic drugs and gut microbiota interact to influence treatment efficacy and tolerability in metabolic syndrome
Gut bacteria may influence how well diabetes drugs work
This narrative review explores how gut microbiota dysbiosis contributes to metabolic syndrome and type 2 diabetes. It synthesizes evidence t…
Your gut bacteria might be the secret reason why some people respond better to diabetes medications than others.
Long-term voglibose use likely caused leukopenia in a 71-year-old man with type 2 diabetes
Switching diabetes drugs reversed low white blood cell counts in a 71-year-old man
This case report describes a 71-year-old male with well-controlled type 2 diabetes who developed leukopenia after long-term voglibose use. W…
A 71-year-old man with type 2 diabetes saw his white blood cell count rise after switching from voglibose to acarbose, suggesting the first …
Alpha-glucosidase inhibitors like acarbose show anti-virulence activity against Candida albicans in vitro
Could common diabetes drugs help stop fungal infections from building tough protective shields?
This systematic review evaluated alpha-glucosidase inhibitors, particularly acarbose, as selective antifungal inhibitors against Candida alb…
A common diabetes drug called acarbose may help break down the tough shields that hide dangerous fungal infections from treatment.